SCHEMBL4368676

SCHEMBL4368676

O=C1OC(c2ccc(OCCC3CC3)cc2)=N/C1=C\c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 3/20 0.51
CSNK2B P67870 3/20 0.51
CSNK2A1 P68400 3/20 0.51
ALDH1A1 P00352 2/20 0.45
PLCG2 P16885 1/20 0.43
HPGD P15428 4/20 0.41
ALOX5 P09917 1/20 0.41
F2 P00734 1/20 0.40
F10 P00742 1/20 0.40
PLG P00747 1/20 0.40
PLAU P00749 1/20 0.40
PLAT P00750 1/20 0.40
KLKB1 P03952 1/20 0.40
MAOB P27338 1/20 0.39
NOTUM Q6P988 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4368683 1.00 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL834188 0.87 CSNK2A2 (0.52) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL2650490 0.86 ALDH1A1 (0.56) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL2650488 0.86 ALDH1A1 (0.56) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL832923 0.79 CSNK2A2 (0.48) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL832924 0.79 CSNK2A2 (0.48) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL10897969 0.73 CSNK2A2 (0.65) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL5814507 0.71 CSNK2A2 (0.55) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL11127621 0.71 CSNK2A2 (0.60) CSNK2A2CSNK2BCSNK2A1ALDH1A1PLCG2
SCHEMBL4365406 0.71 KMT2A (0.58) CSNK2A2CSNK2BCSNK2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908466-B1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO CO LTD (JP) 2014-02-19 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 CSNK2A2 1964/4885CSNK2B 1639/4885CSNK2A1 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.